Vanguard Group Inc. Has $54.56 Million Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Vanguard Group Inc. raised its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,925,213 shares of the company's stock after purchasing an additional 182,125 shares during the quarter. Vanguard Group Inc. owned 7.07% of Kymera Therapeutics worth $54,560,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in KYMR. State Street Corp raised its stake in Kymera Therapeutics by 67.8% during the 2nd quarter. State Street Corp now owns 3,514,438 shares of the company's stock valued at $69,199,000 after purchasing an additional 1,419,877 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Kymera Therapeutics by 34.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,224,686 shares of the company's stock worth $102,874,000 after acquiring an additional 1,329,481 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Kymera Therapeutics by 19.7% in the first quarter. Wellington Management Group LLP now owns 3,225,749 shares of the company's stock worth $136,514,000 after acquiring an additional 530,935 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Kymera Therapeutics by 136.3% in the first quarter. Dimensional Fund Advisors LP now owns 739,991 shares of the company's stock worth $21,925,000 after acquiring an additional 426,831 shares during the last quarter. Finally, BlackRock Inc. increased its stake in shares of Kymera Therapeutics by 13.3% in the third quarter. BlackRock Inc. now owns 3,204,682 shares of the company's stock worth $69,767,000 after acquiring an additional 376,248 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, February 23rd. Truist Financial upped their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Wells Fargo & Company downgraded shares of Kymera Therapeutics from an "overweight" rating to an "equal weight" rating and set a $26.00 price target on the stock. in a research note on Tuesday, December 19th. JPMorgan Chase & Co. increased their target price on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. Finally, Bank of America downgraded shares of Kymera Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $45.00 to $30.00 in a research report on Wednesday, January 3rd. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics has an average rating of "Moderate Buy" and an average price target of $39.89.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR traded up $1.24 during mid-day trading on Tuesday, hitting $37.61. The company had a trading volume of 494,947 shares, compared to its average volume of 768,261. The business's 50-day simple moving average is $38.91 and its 200-day simple moving average is $26.77. Kymera Therapeutics, Inc. has a 12 month low of $9.60 and a 12 month high of $45.31. The firm has a market cap of $2.30 billion, a P/E ratio of -14.92 and a beta of 2.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.19. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The business had revenue of $47.90 million during the quarter, compared to analysts' expectations of $41.94 million. During the same quarter last year, the company earned ($0.60) earnings per share. The firm's revenue was up 197.5% on a year-over-year basis. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.16 EPS for the current year.

Insider Buying and Selling

In related news, Director Bruce Booth sold 71,764 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the transaction, the director now owns 806,697 shares of the company's stock, valued at $32,638,960.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Bruce Booth sold 71,764 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the transaction, the director now owns 806,697 shares of the company's stock, valued at $32,638,960.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 10,000 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $30.05, for a total transaction of $300,500.00. The disclosure for this sale can be found here. Insiders sold 484,051 shares of company stock valued at $19,924,711 over the last quarter. Corporate insiders own 16.67% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.